UPLOAD Filing
VERTEX PHARMACEUTICALS INC / MA
Date: May 7, 2025 · CIK: 0000875320 · Accession: 0000000000-25-004827
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Vertex Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 0-19319 Dear Charles Wagner:
May 7, 2025
Charles Wagner Executive Vice President and Chief Financial Officer Vertex Pharmaceuticals, Inc. 50 Northern Avenue Boston, MA 02210
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 7, 2025 Charles Wagner Executive Vice President and Chief Financial Officer Vertex Pharmaceuticals, Inc. 50 Northern Avenue Boston, MA 02210 Re: Vertex Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 0-19319 Dear Charles Wagner: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>